Anti-Human Aven (NT)

Anti-Human Aven (NT)

Product No.: A253

[product_table name="All Top" skus="A253"]

- -
- -
Target
Aven
Product Type
Polyclonal Antibody
Alternate Names
Apoptosis caspase activation inhibitor
Applications
IHC FFPE
,
WB

- -
- -
Select Product Size

Data

- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Rabbit
Immunogen
PN:A267
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Rabbit Anti-Human Aven recognizes an epitope near the N-terminus of human, mouse and rat Aven. This polyclonal antibody was purified using affinity chromatography.
Background
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. Aven is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that Aven functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that Aven impedes Apaf-1-mediated caspase activation. Higher levels of Aven mRNA are seen in patients with acute leukemia than in control patients, suggesting that Aven may be useful as a prognostic indicator in leukemia patients. Despite its predicted molecular weight, Aven often migrates at 55 kDa in SDS-PAGE.

References & Citations

1. Lockshin, RA. et al. (2000) Cell Death Differ. 7:2-7.
2. Chau, BN. et al. (2000) Mol. Cell 6:31-40.
3. Paydas, S. et al. (2003) Ann. Oncology 14:1045-50.
IHC FFPE
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.